Caplyta Dosing
The recommended dosage of Caplyta (lumateperone) is 42 mg administered orally once daily with or without food, with no titration required. 1
Standard Dosing
- 42 mg once daily (oral administration)
- Can be taken with or without food
- No dose titration necessary 1
Dose Adjustments for Drug Interactions
When Caplyta is coadministered with CYP3A4 inhibitors, dose reduction is mandatory:
- Strong CYP3A4 inhibitors: Reduce to 10.5 mg once daily 1
- Moderate CYP3A4 inhibitors: Reduce to 21 mg once daily 1
Hepatic Impairment
For patients with moderate or severe hepatic impairment (Child-Pugh class B or C), reduce the dose to 21 mg once daily. 1
- Mild hepatic impairment (Child-Pugh A): No dose adjustment required
- Moderate to severe hepatic impairment (Child-Pugh B or C): 21 mg once daily
Renal Impairment
The FDA label does not specify dose adjustments for renal impairment, suggesting that standard dosing (42 mg once daily) can be used across all levels of renal function. This is consistent with lumateperone's primary hepatic metabolism rather than renal clearance.
Elderly Patients
No specific dose adjustment is recommended for elderly patients in the FDA labeling. However, elderly patients with dementia-related psychosis should not receive Caplyta due to increased mortality risk 1. The standard 42 mg dose applies to elderly patients being treated for approved indications (schizophrenia or bipolar depression).
Important Safety Considerations
- Caplyta carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis 1
- Monitor all patients for suicidal thoughts and behaviors, particularly during initial treatment 1
- The medication is contraindicated in patients with hypersensitivity to lumateperone 1
Available Formulations
Caplyta capsules are available in three strengths to accommodate dose adjustments 1:
- 42 mg (blue cap/white body)
- 21 mg (white cap/white body)
- 10.5 mg (light pink cap/light pink body)